Thomas D Giles

Summary

Affiliation: Tulane University
Country: USA

Publications

  1. doi request reprint Prevention of type 2 diabetes mellitus to reduce cardiovascular morbidity and mortality: a review of the evidence
    Thomas D Giles
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 11:512-9. 2009
  2. doi request reprint Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study
    Thomas D Giles
    Department of Medicine, Tulane University, New Orleans, LA, USA Electronic address
    Lancet 383:1889-98. 2014
  3. pmc The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension
    Ramprasad Kandavar
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA
    J Am Soc Hypertens 5:161-5. 2011
  4. doi request reprint Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial
    Thomas D Giles
    Tulane University, New Orleans, LA
    J Clin Hypertens (Greenwich) 15:687-93. 2013
  5. doi request reprint Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis
    Thomas D Giles
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA
    J Clin Hypertens (Greenwich) 14:299-306. 2012
  6. ncbi request reprint A perspective on telmisartan and cardiovascular risk
    Thomas D Giles
    Division of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Rev Cardiovasc Med 8:154-9. 2007
  7. ncbi request reprint Effects of thiazolidinediones on blood pressure
    Thomas D Giles
    Section of Cardiology, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Curr Hypertens Rep 9:332-7. 2007
  8. pmc The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker mo
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, Louisiana, USA
    Blood Press Monit 16:87-95. 2011
  9. doi request reprint Fixed-dose combination therapy of nebivolol and valsartan for the treatment of hypertension
    Gary E Sander
    a Heart and Vascular Institute, Department of Medicine, Tulane University Medical Center, New Orleans, LA, USA
    Expert Rev Cardiovasc Ther 14:563-72. 2016
  10. doi request reprint What is the blood pressure goal for the elder patient 75 years of age or older?
    Gary E Sander
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA
    Curr Cardiol Rep 13:485-91. 2011

Collaborators

Detail Information

Publications54

  1. doi request reprint Prevention of type 2 diabetes mellitus to reduce cardiovascular morbidity and mortality: a review of the evidence
    Thomas D Giles
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 11:512-9. 2009
    ..A large ongoing study is investigating whether therapy with an oral antidiabetic drug or an angiotensin II receptor blocker reduces the incidence of new-onset diabetes and cardiovascular events in high-risk patients...
  2. doi request reprint Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study
    Thomas D Giles
    Department of Medicine, Tulane University, New Orleans, LA, USA Electronic address
    Lancet 383:1889-98. 2014
    ..We assessed the efficacy and safety of a fixed-dose combination of a vasodilating β blocker (nebivolol) and an angiotensin II receptor blocker (valsartan) in adults with hypertension...
  3. pmc The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension
    Ramprasad Kandavar
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA
    J Am Soc Hypertens 5:161-5. 2011
    ..05). IGF-1 and endothelial progenitor cells were unchanged by treatment. Plasma ADMA and augmentation index are increased in a dose-dependent fashion by MET but not with NEB...
  4. doi request reprint Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial
    Thomas D Giles
    Tulane University, New Orleans, LA
    J Clin Hypertens (Greenwich) 15:687-93. 2013
    ..001) and SBP (-13.7 mm Hg vs -5.5 mm Hg, P<.001). Total AE rates were 34.7% (nebivolol) and 32.2% (placebo). Nebivolol monotherapy is efficacious and well tolerated in adults younger than 55 years of age with increased DBP...
  5. doi request reprint Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis
    Thomas D Giles
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA
    J Clin Hypertens (Greenwich) 14:299-306. 2012
    ..Although the addition of aliskiren to valsartan did not significantly alter dipper status, our data suggest an increased contribution of the renin-angiotensin-aldosterone system to the nondipper status of hypertensive patients...
  6. ncbi request reprint A perspective on telmisartan and cardiovascular risk
    Thomas D Giles
    Division of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Rev Cardiovasc Med 8:154-9. 2007
    ....
  7. ncbi request reprint Effects of thiazolidinediones on blood pressure
    Thomas D Giles
    Section of Cardiology, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Curr Hypertens Rep 9:332-7. 2007
    ..A significant proportion of patients with type 2 diabetes mellitus and BP mildly above target range might be successfully treated for both processes with a single drug...
  8. pmc The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker mo
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, Louisiana, USA
    Blood Press Monit 16:87-95. 2011
    ..Home BP was measured on the morning of clinic visits to minimize differences that timing might have on home versus office BP measures...
  9. doi request reprint Fixed-dose combination therapy of nebivolol and valsartan for the treatment of hypertension
    Gary E Sander
    a Heart and Vascular Institute, Department of Medicine, Tulane University Medical Center, New Orleans, LA, USA
    Expert Rev Cardiovasc Ther 14:563-72. 2016
    ..This article will describe the properties of nebivolol that make it unique and separate it from other β-blockers, and will further support the pharmacological advantages of this particular combination. ..
  10. doi request reprint What is the blood pressure goal for the elder patient 75 years of age or older?
    Gary E Sander
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA
    Curr Cardiol Rep 13:485-91. 2011
    ..It is also appropriate to initiate treatment with lower doses of antihypertensive agents and to bring the pressure down more slowly, monitoring for orthostatic hypotension, impaired cognition, and electrolyte abnormalities...
  11. doi request reprint Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, LA, USA
    Congest Heart Fail 16:111-7. 2010
    ..2% vs 12.8%), and weight gain (2.56+/-4.62 kg vs 0.86+/-3.85 kg) were observed than with glyburide...
  12. doi request reprint Digital plethysmography and arginine metabolism in prehypertension: effect of nebivolol therapy
    Ramprasad Kandavar
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA
    J Clin Hypertens (Greenwich) 17:14-9. 2015
    ..Nebivolol therapy is associated with digital vasodilation and increased NO production, as depicted by increased levels of l-citruline and mean digital blood flow...
  13. ncbi request reprint Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome
    Thomas D Giles
    Section of Cardiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 7:669-78. 2005
    ..Glucose-lowering agents may be indicated, and drugs such as metformin and thiazolidinediones, which reduce insulin resistance, should form the basis of therapy. Carefully chosen therapy will effectively improve cardiovascular outcomes...
  14. ncbi request reprint Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, LA 70005, USA
    J Clin Hypertens (Greenwich) 9:187-95. 2007
    ..001). Olmesartan did not reduce mean SeDBP significantly compared with valsartan, although more patients attained blood pressure goal with olmesartan (P=.031). At week 12, all agents lowered blood pressure equivalently...
  15. ncbi request reprint Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease
    Thomas D Giles
    Division of Cardiology, Tulane University School of Medicine, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 8:2-16. 2006
    ..Other cardiovascular therapies that may improve NO bioactivity include statins, l-arginine, and nonpharmacologic approaches such as exercise and dietary changes...
  16. ncbi request reprint Should we redefine hypertension?
    Thomas D Giles
    Department of Medicine, Tulane University School of Medicine, 109 Holly Drive, Metairie, LA 70005, USA
    Curr Cardiol Rep 8:395-8. 2006
    ..This definition of hypertension will permit physicians to treat patients with the goal of reducing global risk for myocardial infarction, stroke, and chronic kidney disease...
  17. doi request reprint Definition and classification of hypertension: an update
    Thomas D Giles
    Tulane University School of Medicine, Metairie, LA 7005, USA
    J Clin Hypertens (Greenwich) 11:611-4. 2009
    ..This paper discusses the logic underlying the refinements in the definition of hypertension...
  18. ncbi request reprint Circadian rhythm of blood pressure and the relation to cardiovascular events
    Thomas D Giles
    Louisiana State University Health Sciences Center, New Orleans, 70112, USA
    J Hypertens Suppl 24:S11-6. 2006
    ....
  19. ncbi request reprint Expanding the definition and classification of hypertension
    Thomas D Giles
    Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 7:505-12. 2005
    ..We believe it would be preferable to classify all individuals as either normal or hypertensive, based on their cardiovascular evaluation, using the four categories of normal and stages 1, 2, and 3 hypertension...
  20. ncbi request reprint Diabetes mellitus and heart failure
    Gary E Sander
    Section of Cardiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    Am Heart Hosp J 1:273-80. 2003
    ....
  21. ncbi request reprint Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations
    Thomas D Giles
    Section of Cardiology, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA 70112, USA
    Cardiol Clin 22:553-68. 2004
    ..Such action will result in great benefit for patients by reducing morbidity and mortality and improving quality of life and will reduce the financial burden that is associated with this epidemic disease...
  22. ncbi request reprint ALLHAT and ANBP2: what have we learned from recent mega-trials?
    Gary E Sander
    Section of Cardiology, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112 2825, USA
    Am J Geriatr Cardiol 12:267-71. 2003
  23. doi request reprint Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins
    Thomas D Giles
    Heart and Vascular Institute, Tulane University Medical Center, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 14:198-205. 2012
    ..Possible pharmacological interventions to restore normal function are suggested...
  24. ncbi request reprint Applying the strategy of combination antihypertensive therapy to special populations
    Thomas D Giles
    Section of Cardiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 8:2-3. 2006
  25. doi request reprint The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol
    Thomas D Giles
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Am J Med 123:S16-20. 2010
    ..g., elderly patients, African American patients), a vasodilating beta-blocker may be a particularly appropriate choice for these patient groups...
  26. ncbi request reprint Examining therapeutic goals: population versus individual-based approaches
    Thomas D Giles
    Department of Medicine, Louisiana State University School of Medicine, New Orleans, Louisiana 70112, USA
    Am J Hypertens 16:26S-30S. 2003
    ..Ultimately, the treatment decisions should be tailored to each patient, integrating as much information as possible concerning the patient's history, risk, pathophysiology, and lifestyle...
  27. ncbi request reprint Rationale for combination therapy as initial treatment for hypertension
    Thomas D Giles
    Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 5:4-11. 2003
    ....
  28. ncbi request reprint Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy
    Thomas D Giles
    Division of Cardiology, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Rev Cardiovasc Med 8:S14-21. 2007
    ..This article examines the results of clinical trials of ACE inhibitors and ARBs and assesses the potential for improving outcomes through a more global inhibition of the RAS with renin inhibitors...
  29. doi request reprint The need for defining- and redefining- hypertension: beyond the numbers
    Thomas D Giles
    Cardiovascular Research, Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    Postgrad Med 118:21-5. 2005
    ..In this article, Drs Giles and Sander review the current definitions of hypertension in clinical practice and its evaluation in light of total cardiovascular risk...
  30. doi request reprint Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension
    Thomas D Giles
    Department of Medicine, Tulane University, New Orleans, LA, USA Electronic address
    J Am Soc Hypertens 9:845-54. 2015
    ..001 and P = .005). The implications of the renin-angiotensin-aldosterone system effects of this beta blocker-angiotensin receptor blocker combination should be explored further. ..
  31. doi request reprint Resistant hypertension: concepts and approach to management
    Gary E Sander
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA
    Curr Hypertens Rep 13:347-55. 2011
    ..What is most important is that treatment regimens should be targeted to specific patient profiles...
  32. ncbi request reprint Assessment of global risk: a foundation for a new, better definition of hypertension
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 8:5-14; quiz 39. 2006
    ..This revision of the definition of hypertension and the need to assess BP levels in the context of global cardiovascular risk should lead to earlier detection of at-risk patients...
  33. doi request reprint Use of beta-blockers for heart failure in patients with diabetes mellitus
    Thomas D Giles
    Cardiovascular Research Louisiana State University Health Science Center, 1542 Tulane Ave, Rm 331E, New Orleans, LA 70112, USA
    Postgrad Med 112:32-7. 2002
    ..These observations strongly support a role for the use of beta-blockers in patients with both heart failure and diabetes...
  34. doi request reprint Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, Louisiana, USA
    J Card Fail 14:445-52. 2008
    ..We compared the effects of pioglitazone and glyburide on cardiac function in patients with type 2 diabetes, systolic dysfunction, and New York Heart Association (NYHA) functional Class II/III HF...
  35. ncbi request reprint The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions
    Gary E Sander
    Section of Cardiology, Department of Medicine, Tulane Medical Center, New Orleans, LA 70112, USA
    Am J Geriatr Cardiol 15:255-9. 2006
  36. ncbi request reprint Medical management of myocardial ischemia
    Gary E Sander
    Cardiovascular Research Laboratory, Louisiana State University Health Sciences Center, New Orleans, LA 70112 2825, USA
    Am J Geriatr Cardiol 14:205-9. 2005
  37. ncbi request reprint Alcohol--a cardiovascular drug?
    Thomas D Giles
    Louisiana State University Health Services, New Orleans, LA 70112, USA
    Am J Geriatr Cardiol 14:154-8. 2005
  38. ncbi request reprint Ximelagatran: light at the end of the tunnel or the next tunnel?
    Gary E Sander
    Section of Cardiology, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112 2825, USA
    Am J Geriatr Cardiol 13:221-4. 2004
  39. ncbi request reprint Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial
    Thomas D Giles
    LSU School of Medicine, New Orleans, Louisiana, USA
    Am J Hypertens 16:460-6. 2003
    ....
  40. ncbi request reprint Statin therapy in the elderly-the evidence mounts
    Gary E Sander
    Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    Am J Geriatr Cardiol 12:65-7. 2003
  41. ncbi request reprint Update on the management of diabetes and hypertension
    Thomas D Giles
    Louisiana State University Medical Center, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 4:3-10. 2002
  42. doi request reprint Prehypertension: Defining the Transitional Phenotype
    Camilo Fernandez
    Tulane University School of Medicine, 1440 Canal St, New Orleans, LA, 70112, USA
    Curr Hypertens Rep 18:2. 2016
    ..Our current review addresses these aspects of the pathophysiology or prehypertension on its progression to hypertension and suggests a new approach to its classification. ..
  43. doi request reprint Beta-blocker therapy for patients with ventricular heart failure and reduced systolic function
    Thomas D Giles
    Division of Cardiology, Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    Postgrad Med 114:18-29. 2003
    ..Other agents such as angiotensin II-receptor blockers and mineralocorticoid (aldosterone) receptor antagonists may also be important...
  44. ncbi request reprint An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, Louisiana, USA
    J Am Soc Hypertens 3:395-402. 2009
    ..OM had the greatest early efficacy, with numerically greater mean reductions in DBP and SBP, and a higher proportion of Black and non-Black patients achieving goal BP of 140/90mm Hg at week 8...
  45. ncbi request reprint The patient with diabetes mellitus and heart failure: at-risk issues
    Thomas D Giles
    Section of Cardiovascular Research, Louisiana State University Health Science Center, New Orleans, Louisiana 70112, USA
    Am J Med 115:107S-110S. 2003
    ..Thus the risk-benefit ratio of using TZDs in patients who have diabetes and heart failure must be carefully considered in this patient population with comorbid disorders...
  46. ncbi request reprint Methodological evaluation of the noninvasive estimation of central systolic blood pressure in nontreated patients: the Bogalusa Heart Study
    Camilo Fernandez
    aDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine bHeart and Vascular Institute, Tulane University School of Medicine, New Orleans, Louisiana cHeartGEN Institute dHeart and Vascular Center, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Blood Press Monit . 2016
    ....
  47. ncbi request reprint Cardiovascular Complications of Collagen Vascular Disease
    Gary E Sander
    Section of Cardiology, Department of Medicine, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA 70112, USA
    Curr Treat Options Cardiovasc Med 4:151-159. 2002
    ..Cardiac autonomic neuropathy and conduction disturbances are common in people with heart disease related to systemic sclerosis and human leukocyte antigen B27; these patients should be monitored carefully for evidence of dysrhythmias...
  48. doi request reprint Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension
    Gary E Sander
    Tulane University School of Medicine, From the Heart and Vascular Institute, Department of Medicine, 1430 Tulane Ave, New Orleans, LA 70112, USA
    Expert Opin Pharmacother 16:763-70. 2015
    ..This review describes a recently completed trial establishing the efficacy of the nebivolol/valsartan combination...
  49. doi request reprint Beta-blockers for preventing sudden cardiac death
    Thomas D Giles
    Division of Cardiovascular Research, Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    Postgrad Med 114:30-4. 2003
    ..Clinical evidence reveals the association between beta-blockade and improved survival, and trials explore the role for beta-blockers in the prevention of sudden cardiac death...
  50. ncbi request reprint The Trial of Preventing Hypertension (TROPHY) as seen through the eyes of the Hypertension Writing Group's expanded definition of hypertension
    Thomas D Giles
    Department of Medicine, Louisiana State University Medical Center, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 8:441-3. 2006
  51. ncbi request reprint Hypertension and heart failure sine heart failure. The ACC/AHA guidelines: a misadventure in the lexicography of cardiomyopathy and heart failure, particularly for the hypertensive
    Thomas D Giles
    Louisiana State University Medical Center, 1542 Tulane Avenue, Room 331E, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 5:280-1. 2003
  52. ncbi request reprint Hypertension and lipids: lipid factors in the hypertension syndrome
    Gary E Sander
    Cardiovascular Research Laboratory, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA 70112, USA
    Curr Hypertens Rep 4:458-63. 2002
    ..Recognition and identification of multiple risk factors and appropriate treatment in a manner that minimizes excessive oxidative stress is critical to the maintenance of normal endothelial cell function and cardiovascular risk reduction...
  53. ncbi request reprint Atherosclerotic cardiovascular disease: new approaches to risk assessment and intervention. Introduction
    Thomas D Giles
    Department of Medicine, Louisiana State University Medical Center, New Orleans, Louisiana 70112, USA
    Am J Med 112:1S-2S. 2002
  54. ncbi request reprint Noncardiac drugs and QTc interval prolongation: an often unrecognized risk factor for adverse cardiovascular outcomes
    Gary E Sander
    Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    Am J Geriatr Cardiol 11:197-202. 2002